ArticleInvestigational new drugs2016

Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.

Neeraj Gupta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.